Romosozumab/Denosumab Study for Premenopausal IOP
NCT04800367 is a phase 2 interventional trial sponsored by Columbia University. As of 21 Nov 2026, it is active and no longer recruiting. It studies Denosumab and Romosozumab Prefilled Syringe [Evenity] in Premenopausal Idiopathic Osteoporosis. The registry lists an enrollment of 30 participants at 1 site in 1 country. The registry lists a start date of 12 Mar 2021 and a primary completion date of 31 Mar 2027.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT04800367 |
| Status | Active not recruiting |
| Phase | Phase 2 |
| Study type | Interventional trial |
| Lead sponsor | Columbia University |
| Enrollment | 30 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Premenopausal Idiopathic Osteoporosis |
| Drugs | Denosumab and Romosozumab Prefilled Syringe [Evenity] |
| Start | 12 Mar 2021 |
| Primary completion | 31 Mar 2027 |
| Study completion | 31 Mar 2028 |
| Last update posted | 27 Feb 2026 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Adi Cohen, MD
Columbia University
Principal Investigator - Elizabeth Shane, MD
Columbia University
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Columbia University Irving Medical Center
New York
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT04800367
Each answer restates registry values shown on this page.
What is NCT04800367?
NCT04800367 is a phase 2 interventional trial sponsored by Columbia University. It studies Denosumab and Romosozumab Prefilled Syringe [Evenity] in Premenopausal Idiopathic Osteoporosis.
Is NCT04800367 recruiting?
As of 21 Nov 2026, it is active and no longer recruiting.
Who leads NCT04800367?
The registry names Adi Cohen, MD (principal investigator, Columbia University) and Elizabeth Shane, MD (principal investigator, Columbia University) as overall officials.
Where does NCT04800367 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT04800367 study?
The registered drug and biological interventions are Denosumab and Romosozumab Prefilled Syringe [Evenity].
When is NCT04800367 expected to complete?
The registry lists a primary completion date of 31 Mar 2027 and a study completion date of 31 Mar 2028. The sponsor last updated the record on 27 Feb 2026.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.